Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Osteoporosis Drugs Don’t Reduce Overall Mortality

Megan Brooks  |  

NEW YORK (Reuters Health)—Anti-fracture medications do not reduce overall mortality in older patients with osteoporosis, according to an updated systematic review and meta-analysis. “This meta-analysis suggests drug treatments, including treatment with bisphosphonates, for osteoporosis should be recommended only for the prevention of fracture and not for any additional reduction in mortality,” researchers write in JAMA…

Shingles Vaccine Not the Only Immunization Linked with Gout Flare

Marilynn Larkin  |  

NEW YORK (Reuters Health)—The recombinant shingles vaccine (RZV) is associated with an increased risk of gout flare, and a new study suggests other vaccines may trigger flares as well, researchers say. “Our findings are novel because for the first time, we have identified a trigger for gout flares that presumably acts through [an inflammatory] pathway,…

Improved Pregnancy Outcomes for Women with SLE

  |  

Recent research indicates that previous concerns about mortality associated with pregnancy in women with SLE may no longer be applicable. In the study, researchers found a significant decline in the in-hospital maternal mortality rate of women with SLE and a decrease in their length of non-delivery related hospitalization over the past two decades…

FDA Approves AbbVie’s New Rheumatoid Arthritis Drug

Reuters Staff  |  

(Reuters)—The U.S. Food and Drug Administration (FDA) on Friday approved AbbVie Inc.’s new treatment for rheumatoid arthritis (RA), a win for the drugmaker seeking to widen its portfolio as its blockbuster flagship therapy Humira (adalimumab)‎‎ faces competition. The drug, Rinvoq (upadacitinib), is a JAK inhibitor. It is set to compete with Pfizer Inc.’s Xeljanz (tofacitinib)…